Several new medications are transforming diabetes management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as leading options. Retatrutide, a double GIP and GLP-1 receptor activator, exhibits substantial fat reduction coupled with better glucose regulation. Cagrillintide, a GLP-1 activator, is presently in research trials,